AR041635A1 - Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen - Google Patents
Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR041635A1 AR041635A1 ARP030103764A ARP030103764A AR041635A1 AR 041635 A1 AR041635 A1 AR 041635A1 AR P030103764 A ARP030103764 A AR P030103764A AR P030103764 A ARP030103764 A AR P030103764A AR 041635 A1 AR041635 A1 AR 041635A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- formula
- halo
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
Abstract
La presente se refiere compuestos que en general tienen afinidad con el receptor de 5-HT6, composiciones farmacéuticas que contienen tales compuestos, a métodos para el uso de los mismos en calidad de agentes terapéuticos. Para trastornos del sistema nervioso central. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1 y R2 con independencia entre sí son hidrógeno, alquilo, arilo, acilo, halo, nitro, amino, ciano, alcoxi, hidroxi, ariloxi, alquiltio, ariltio, tiol, carbonilamino, aminocarbonilo, o haloalquilo; R3 y R4 con independencia entre sí son hidrógeno, halo, alquilo, acilo, arilo, o arilalquilo; n es un número de 0 a 4; R6 con independencia de su aparición es hidrógeno, alquilo, alcoxi, o halo; R7 y R8 con independencia entre sí son hidrógeno o alquilo; y R9 es hidrógeno, alquilo, o arilalquilo; o un isómero individual, una mezcla racémica o no racémica de isómeros, un principio activo latente (prodrug) o una sal o un solvato farmacéuticamente aceptables del mismo. Reivindicación 14: Un proceso de obtención de un compuesto de la fórmula (1) según la reivindicación 1, que consiste en poner en contacto un 4-halobencenosulfonil-indol de la fórmula (2), en la que X es halo, con un piperazina de la fórmula (3), para obtener un compuesto de la fórmula (1), en la que n, R1, R2, R3, R4, R6, R7, R8 y R9 tienen los significados definidos en la reivindicación 1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41936902P | 2002-10-18 | 2002-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR041635A1 true AR041635A1 (es) | 2005-05-26 |
Family
ID=32108067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030103764A AR041635A1 (es) | 2002-10-18 | 2003-10-16 | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen |
Country Status (21)
Country | Link |
---|---|
US (1) | US7022708B2 (es) |
EP (1) | EP1556037B1 (es) |
JP (1) | JP2006505559A (es) |
KR (1) | KR20050073560A (es) |
CN (1) | CN1309384C (es) |
AR (1) | AR041635A1 (es) |
AT (1) | ATE344030T1 (es) |
AU (1) | AU2003283265B2 (es) |
BR (1) | BR0315317A (es) |
CA (1) | CA2501172A1 (es) |
DE (1) | DE60309498T2 (es) |
ES (1) | ES2274285T3 (es) |
GT (1) | GT200300226A (es) |
MX (1) | MXPA05004128A (es) |
PA (1) | PA8586401A1 (es) |
PE (1) | PE20040691A1 (es) |
PL (1) | PL376479A1 (es) |
RU (1) | RU2324693C2 (es) |
TW (1) | TW200418456A (es) |
UY (1) | UY28026A1 (es) |
WO (1) | WO2004035047A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4187642B2 (ja) * | 2001-06-07 | 2008-11-26 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht6受容体親和性を有する新規インドール誘導体 |
PL209872B1 (pl) | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
EP1737461B1 (en) | 2004-03-15 | 2012-12-12 | PTC Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US8013006B2 (en) | 2004-07-14 | 2011-09-06 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
AR052308A1 (es) * | 2004-07-16 | 2007-03-14 | Lundbeck & Co As H | Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto |
MX2007000762A (es) | 2004-07-22 | 2007-04-02 | Ptc Therapeutics Inc | Tienopiridinas para tratamientode hepatitis c. |
ES2643615T3 (es) | 2004-09-30 | 2017-11-23 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos |
US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
DK1919896T3 (da) * | 2005-08-12 | 2010-04-19 | Suven Life Sciences Ltd | Aminoarylsulfonamidderivater, som funktionelle 5-HT6-ligander |
RU2429231C2 (ru) * | 2005-08-15 | 2011-09-20 | Вайет | Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6 |
US7923566B2 (en) | 2005-08-16 | 2011-04-12 | Suven Life Sciences Limited | Alternative process for the preparation of losartan |
RU2008127501A (ru) * | 2006-01-13 | 2010-02-20 | Вайет (Us) | Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов |
KR20090079259A (ko) | 2006-11-09 | 2009-07-21 | 에프. 호프만-라 로슈 아게 | 5-ht6 억제제로서 아릴설폰일 피롤리딘 |
CN101578265B (zh) | 2007-01-10 | 2013-05-08 | 霍夫曼-拉罗奇有限公司 | 用作糜蛋白酶抑制剂的磺酰胺衍生物 |
EA017154B1 (ru) * | 2007-10-26 | 2012-10-30 | Сувен Лайф Сайенсиз Лимитед | Аминоарилсульфонамидные соединения и их применение в качестве 5-нтлигандов |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2010032257A1 (en) * | 2008-09-17 | 2010-03-25 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
US9067949B2 (en) | 2011-01-19 | 2015-06-30 | Albany Molecular Research, Inc. | Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia |
DK2838533T3 (da) * | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
EP3057973B1 (en) | 2013-10-15 | 2019-09-04 | Case Western Reserve University | Compositions comprising a 15-pgdh inhibitor for the healing of wounds |
CN104557726B (zh) * | 2013-10-19 | 2019-05-24 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
JP6454346B2 (ja) | 2013-12-20 | 2019-01-16 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族複素環式化合物及び医薬におけるその応用 |
CA2953004C (en) * | 2014-07-08 | 2023-02-21 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
WO2018102552A1 (en) | 2016-11-30 | 2018-06-07 | Case Western Reserve University | Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof |
CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
CN109232362B (zh) * | 2017-07-10 | 2022-12-27 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
CA3237199A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9116732D0 (en) | 1991-08-02 | 1991-09-18 | Fujisawa Pharmaceutical Co | Indole derivatives |
FR2729144A1 (fr) | 1995-01-06 | 1996-07-12 | Smithkline Beecham Lab | Nouvelles diamines, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu' agents anti-arythmiques |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
WO1999002502A2 (en) | 1997-07-11 | 1999-01-21 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
AU3196100A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Heterocyclic sulfonamide derivatives |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
EP1326830A1 (en) * | 2000-10-20 | 2003-07-16 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
US20050176705A1 (en) * | 2000-11-24 | 2005-08-11 | Bromidge Steven M. | Compounds useful in the treatment of cns disorders |
CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物 |
MXPA04012122A (es) * | 2002-06-05 | 2005-04-19 | Hoffmann La Roche | Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores del receptor 5-hidroxitriptamina 6 (5-5-ht6) para tratamiento de trastornos del sistema nervioso central (snc). |
JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
MXPA05002836A (es) * | 2002-09-17 | 2005-05-27 | Hoffmann La Roche | Indoles 2,4-sustituidos y su uso como moduladores 5-ht6. |
-
2003
- 2003-10-13 PL PL03376479A patent/PL376479A1/xx not_active Application Discontinuation
- 2003-10-13 ES ES03775181T patent/ES2274285T3/es not_active Expired - Lifetime
- 2003-10-13 EP EP03775181A patent/EP1556037B1/en not_active Expired - Lifetime
- 2003-10-13 CN CNB2003801014548A patent/CN1309384C/zh not_active Expired - Fee Related
- 2003-10-13 MX MXPA05004128A patent/MXPA05004128A/es active IP Right Grant
- 2003-10-13 DE DE60309498T patent/DE60309498T2/de not_active Expired - Lifetime
- 2003-10-13 KR KR1020057006683A patent/KR20050073560A/ko not_active Application Discontinuation
- 2003-10-13 RU RU2005115115/04A patent/RU2324693C2/ru not_active IP Right Cessation
- 2003-10-13 AT AT03775181T patent/ATE344030T1/de not_active IP Right Cessation
- 2003-10-13 WO PCT/EP2003/011323 patent/WO2004035047A1/en active IP Right Grant
- 2003-10-13 BR BR0315317-7A patent/BR0315317A/pt not_active IP Right Cessation
- 2003-10-13 AU AU2003283265A patent/AU2003283265B2/en not_active Ceased
- 2003-10-13 JP JP2004544204A patent/JP2006505559A/ja active Pending
- 2003-10-13 CA CA002501172A patent/CA2501172A1/en not_active Abandoned
- 2003-10-14 TW TW092128412A patent/TW200418456A/zh unknown
- 2003-10-15 PE PE2003001052A patent/PE20040691A1/es not_active Application Discontinuation
- 2003-10-15 PA PA20038586401A patent/PA8586401A1/es unknown
- 2003-10-16 UY UY28026A patent/UY28026A1/es not_active Application Discontinuation
- 2003-10-16 US US10/687,091 patent/US7022708B2/en not_active Expired - Fee Related
- 2003-10-16 AR ARP030103764A patent/AR041635A1/es not_active Application Discontinuation
- 2003-10-17 GT GT200300226A patent/GT200300226A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0315317A (pt) | 2005-09-06 |
MXPA05004128A (es) | 2005-06-22 |
RU2005115115A (ru) | 2006-01-20 |
AU2003283265B2 (en) | 2009-03-05 |
EP1556037B1 (en) | 2006-11-02 |
US7022708B2 (en) | 2006-04-04 |
UY28026A1 (es) | 2004-04-30 |
GT200300226A (es) | 2004-10-18 |
RU2324693C2 (ru) | 2008-05-20 |
PA8586401A1 (es) | 2005-08-04 |
JP2006505559A (ja) | 2006-02-16 |
TW200418456A (en) | 2004-10-01 |
PL376479A1 (en) | 2005-12-27 |
CN1705480A (zh) | 2005-12-07 |
AU2003283265A1 (en) | 2004-05-04 |
DE60309498T2 (de) | 2007-08-30 |
WO2004035047A1 (en) | 2004-04-29 |
US20040087593A1 (en) | 2004-05-06 |
KR20050073560A (ko) | 2005-07-14 |
ATE344030T1 (de) | 2006-11-15 |
ES2274285T3 (es) | 2007-05-16 |
PE20040691A1 (es) | 2004-10-16 |
EP1556037A1 (en) | 2005-07-27 |
CN1309384C (zh) | 2007-04-11 |
DE60309498D1 (de) | 2006-12-14 |
CA2501172A1 (en) | 2004-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
CU23413B7 (es) | Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos | |
AR035479A1 (es) | Derivados de eteres biarilicos y sus sales, composiciones farmaceuticas que los comprenden y procedimientos para el tratamiento de trastornos o afecciones | |
PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
UY26872A1 (es) | Derivados de la 4- fenil piridina | |
DOP2001000170A (es) | Derivados de tiofeno utiles como agentes anticancesoros | |
PA8593101A1 (es) | Composiciones para el tratamiento de crecimiento celular anormal | |
CU23132A3 (es) | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos | |
PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
UY28374A1 (es) | Agentes terapéuticos | |
PA8480101A1 (es) | Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos | |
AR038044A1 (es) | Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso. | |
UY26968A1 (es) | Agentes terapéuticos | |
AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
UY28144A1 (es) | Agentes terapéuticos | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa | |
ECSP034628A (es) | Formas de sal de amida de acido 3-(4-bromo-2,6-difluorobenciloxi)-5-[3-(4-oirrolidin-1-ilbutil) ureido] isotiazol-4-carboxilico y metodo de produccion | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
AR045156A1 (es) | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos | |
PA8589801A1 (es) | Aminoalcoxiindoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |